Addex Therapeutics GABAB PAM Shows Promise for Chronic Cough

Exciting Developments from Addex Therapeutics

Addex Therapeutics (SWX: ADXN), a dynamic biopharmaceutical company with a focus on neurological disorders, has recently made noteworthy advancements in the treatment of chronic cough. Their innovative approach centers around a gamma-aminobutyric acid subtype B receptor (GABAB) positive allosteric modulator (PAM), which has exhibited promising anti-tussive activity in various preclinical models.

Clinical Insights from Recent Research

In preclinical studies, the GABAB PAM drug candidate has shown a remarkable ability to diminish cough frequency triggered by citric acid. This reduction was complemented by an increase in cough latency, indicating its potential effectiveness. What sets this candidate apart is its performance compared to traditional treatments like nalbuphine, baclofen, and codeine, where it has demonstrated superior tolerability and therapeutic margins.

Presentation of Results at the Upcoming Conference

Excitement surrounds the upcoming presentation at a major cough conference, slated to showcase these significant findings. Dr. Mikhail Kalinichev, Head of Translational Science at Addex, will discuss the compelling data on June 7, emphasizing the promising nature of this GABAB PAM drug candidate as we venture into further studies and clinical trials.

Statements from Addex's Leadership

Dr. Kalinichev expressed enthusiasm, stating that the data collected so far reflects the therapeutic potential of their selective GABAB PAM. He emphasized the need for better treatments for chronic cough, which presents ongoing challenges for many patients. As the data indicates, this candidate could represent a pioneering once-daily treatment option that could significantly benefit patients with refractory chronic cough.

The Allosteric Modulator Approach

The GABAB receptor plays a vital role in cough regulation, with existing treatments demonstrating various side effects and limitations. By focusing on an allosteric modulation, Addex aims to offer higher selectivity and reduced tolerance, enhancing patient outcomes.

About Addex Therapeutics

Addex Therapeutics is at the forefront of clinical-stage biopharmaceutical development, specializing in innovative small molecule allosteric modulators. Their lead candidate, the negative allosteric modulator dipraglurant, is under evaluation for recovery following brain injuries. Furthermore, Addex is engaged in a collaboration with Indivior to develop a GABAB PAM candidate for substance use disorders, successfully passing initial studies.

Contact Information for Inquiries

For those interested in further information about Addex Therapeutics, the following contacts are available:

Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Email: PR@addextherapeutics.com

Mike Sinclair
Partner, Halsin Partners
Telephone: +44 (0)7968 022075
Email: msinclair@halsin.com

Frequently Asked Questions

What is the significance of the GABAB PAM candidate?

The GABAB PAM candidate is significant due to its robust anti-tussive activity, demonstrating a potential breakthrough in treating chronic cough.

How was the GABAB PAM evaluated in preclinical studies?

It was evaluated in models that induced cough, showing a reduction in cough frequency and an increase in cough latency without tolerance.

Who presented the GABAB PAM findings, and when?

Dr. Mikhail Kalinichev presented the findings, with the presentation scheduled for June 7 at a prominent conference focused on cough management.

What advantages does the allosteric modulation approach offer?

Allosteric modulation can provide higher selectivity and better tolerability than traditional agonists, potentially leading to improved treatment outcomes.

Where can I find more information about Addex Therapeutics?

For more information, visit Addex Therapeutics' official website at www.addextherapeutics.com.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.